Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Nov;7(4):214-20.
doi: 10.2174/157340311799960645.

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment

Maria Volkova  1 , Raymond Russell 3rd
Affiliations
Review

Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment

Maria Volkova et al. Curr Cardiol Rev. 2011 Nov.

Abstract

Anthracyclines, such as doxorubicin and idarubicin, remain an important class of chemotherapeutic agents. Unfortunately, their efficacy in treating cancer is limited by a cumulative dose-dependent cardiotoxicity, which can cause irreversible heart failure. In this review, we discuss the pathogenesis and incidence of anthracycline-induced cardiotoxicity as well as methods to detect, prevent and treat the condition.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Cellular mechanisms responsible for increased apoptosis in cardiac myocytes by doxorubicin.
See this image and copyright information in PMC

References

    1. Di Marco A, Cassinelli G, Arcamone F. The discovery of daunorubicin. Cancer. Treat Rep. 1981;4 (65 Suppl ):3–8. - PubMed
    1. Tan C, Tasaka H, Yu KP, Murphy ML, et al. Daunomycin an antitumor antibiotic, in the treatment of neoplastic disease Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20(3 ):333–53. - PubMed
    1. Arcamone F, Cassinelli G, Fantini G, et al. Adriamycin 14-hydroxydaunomycin, a new antitumor antibiotic from S peucetius var caesius. Biotechnol Bioeng. 1969;11(6 ):1101–10. - PubMed
    1. Di Marco A, Gaetani M, Scarpinato B. Adriamycin (NSC-123 127) a new antibiotic with antitumor activity. Cancer Chemother Rep. 1969;53(1 ):33–7. - PubMed
    1. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32(2 ):302–14. - PubMed

MeSH terms